Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes - PubMed (original) (raw)

Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes

G W Arendash et al. Brain Res. 2001.

Abstract

This study provides a comprehensive behavioral characterization during aging of transgenic mice bearing both presenilin-1 (PS1) and amyloid precursor protein (APP(670,671)) mutations. Doubly transgenic mice and non-transgenic controls were evaluated at ages wherein beta-amyloid (Abeta) neuropathology in APP+PS1 mice is low (5-7 months) or very extensive (15-17 months). Progressive cognitive impairment was observed in transgenic mice for both water maze acquisition and radial arm water maze working memory. However, transgenicity did not affect Y-maze alternations, circular platform performance, standard water maze retention, or visible platform recognition at either age, nor did transgenicity affect anxiety levels in elevated plus-maze testing. In sensorimotor tasks, transgenic mice showed a progressive increase in open field activity, a progressive impairment in string agility, and an early-onset impairment in balance beam. None of these sensorimotor changes appeared to be contributory to any cognitive impairments observed, however. Non-transgenic mice showed no progressive behavioral change in any measure evaluated. Given the age-related cognitive impairments presently observed in APP+PS1 transgenic mice and their progressive Abeta deposition/neuroinflammation, Abeta neuropathology could be involved in these progressive cognitive impairments. As such, the APP+PS1 transgenic mouse offers unique opportunities to develop therapeutics to treat or prevent Alzheimer's Disease through modulation of Abeta deposition/neuroinflammation.

PubMed Disclaimer

Similar articles

• Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice.
  Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RG, Shen J. Saura CA, et al. J Neurosci. 2005 Jul 20;25(29):6755-64. doi: 10.1523/JNEUROSCI.1247-05.2005. J Neurosci. 2005. PMID: 16033885 Free PMC article.
• Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease.
  King DL, Arendash GW, Crawford F, Sterk T, Menendez J, Mullan MJ. King DL, et al. Behav Brain Res. 1999 Sep;103(2):145-62. doi: 10.1016/s0166-4328(99)00037-6. Behav Brain Res. 1999. PMID: 10513583
• Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice.
  Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen CH, Duff K, Nixon RA, Gruen RJ, Wisniewski T. Sadowski M, et al. J Neuropathol Exp Neurol. 2004 May;63(5):418-28. doi: 10.1093/jnen/63.5.418. J Neuropathol Exp Neurol. 2004. PMID: 15198121
• Metabolism of presenilin 1: influence of presenilin 1 on amyloid precursor protein processing.
  Borchelt DR. Borchelt DR. Neurobiol Aging. 1998 Jan-Feb;19(1 Suppl):S15-8. doi: 10.1016/s0197-4580(98)00026-8. Neurobiol Aging. 1998. PMID: 9562461 Review.
• Transgenic mouse models of Alzheimer's disease.
  Sirinathsinghji DJ. Sirinathsinghji DJ. Biochem Soc Trans. 1998 Aug;26(3):504-8. doi: 10.1042/bst0260504. Biochem Soc Trans. 1998. PMID: 9765905 Review. No abstract available.

Cited by

• Tannic acid is a natural β-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice.
  Mori T, Rezai-Zadeh K, Koyama N, Arendash GW, Yamaguchi H, Kakuda N, Horikoshi-Sakuraba Y, Tan J, Town T. Mori T, et al. J Biol Chem. 2012 Feb 24;287(9):6912-27. doi: 10.1074/jbc.M111.294025. Epub 2012 Jan 4. J Biol Chem. 2012. PMID: 22219198 Free PMC article.
• Specific spatial learning deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta -amyloid deposits but do not form plaques.
  Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, Koistinaho J, Bures J, Higgins LS. Koistinaho M, et al. Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14675-80. doi: 10.1073/pnas.261562998. Epub 2001 Nov 27. Proc Natl Acad Sci U S A. 2001. PMID: 11724968 Free PMC article.
• Alzheimer disease models and human neuropathology: similarities and differences.
  Duyckaerts C, Potier MC, Delatour B. Duyckaerts C, et al. Acta Neuropathol. 2008 Jan;115(1):5-38. doi: 10.1007/s00401-007-0312-8. Epub 2007 Nov 16. Acta Neuropathol. 2008. PMID: 18038275 Free PMC article. Review.
• Enhanced cognitive activity--over and above social or physical activity--is required to protect Alzheimer's mice against cognitive impairment, reduce Abeta deposition, and increase synaptic immunoreactivity.
  Cracchiolo JR, Mori T, Nazian SJ, Tan J, Potter H, Arendash GW. Cracchiolo JR, et al. Neurobiol Learn Mem. 2007 Oct;88(3):277-94. doi: 10.1016/j.nlm.2007.07.007. Epub 2007 Aug 21. Neurobiol Learn Mem. 2007. PMID: 17714960 Free PMC article.
• Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-β Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer's Disease Pathology.
  Reale M, D'Angelo C, Costantini E, Di Nicola M, Yarla NS, Kamal MA, Salvador N, Perry G. Reale M, et al. J Alzheimers Dis. 2018;62(1):467-476. doi: 10.3233/JAD-170999. J Alzheimers Dis. 2018. PMID: 29439355 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Research Materials

  • NCI CPTC Antibody Characterization Program